First-pass extracted concept

RNA alternative splicing

Candidate: concept label1 source documents4 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

RNA alternative splicing (AS) has emerged as a central post-transcriptional mechanism driving antigenic diversity and immune escape.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1mechanismsupports2025Source 1DOI PubMed

Aberrant activity of splicing regulators disrupts canonical exon selection, leading to altered receptor signaling or secretion of soluble decoy isoforms that evade immune recognition.

Claim 2mechanismsupports2025Source 1DOI PubMed

Alternative-splicing-generated isoforms remodel surface antigen structure and function across therapeutic targets including CD19, CD20, CD22, EGFR/HER2, VEGF, and PD-1/PD-L1, thereby promoting resistance to monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors.

Claim 3mechanismsupports2025Source 1DOI PubMed

RNA alternative splicing is presented as a central post-transcriptional mechanism driving antigenic diversity and immune escape in antibody-based cancer therapy contexts.

Claim 4translational frameworksupports2025Source 1DOI PubMed

Understanding splicing-driven antigenic plasticity provides a framework for RNA-informed precision antibody therapies designed to restore antigen expression, overcome immune escape, and enhance durable clinical responses.